Abstract：Objective：To observe the clinical effect of the therapy of Wei'erkang Tablets combined with Rebamipide on chronic superficial gastritis (CSG) of spleen- stomach weakness type. Methods：A total of 84 CSG patients of spleen-stomach weakness type were divided into the control group and the treatment group according to the random number table method，with 42 cases in each group. The control group was given Rebamipide for treatment，and the treatment group was treated with Wei'erkang Tablets combined with Rebamipide. Before and after treatment， the traditional Chinese medicine (TCM) syndrome scores， scores of Visual Analogue Scale (VAS) and Activities of Daily Living (ADL) scale and levels of serum prostaglandin E2 (PGE2) and epidermal growth factor (EGF) were compared between the two groups； the clinical effects， incidence of adverse reactions and recurrence of disease in both groups were evaluated. Results： The total effective rate was 97.62% in the treatment group， higher than that of 80.95% in the control group (P＜0.05). After treatment，the TCM syndrome scores，VAS scores and EGF levels in both groups were decreased when compared with those before treatment (P＜0.05)，the ADL scores and serum PGE2 levels increased (P＜0.05)； ADL scores and serum PGE2 levels in the treatment group were higher than those in the control group after treatment (P＜0.05)，and the EGF levels，TCM syndrome score and VAS score were lower than those in the control group (P＜0.05). The incidence of adverse reactions and recurrence of disease were 2.38% and 0 in the treatment group，lower than those of 16.67% and 11.76% in the control group， respectively. Conclusion： The therapy of Wei'erkang Tablets combined with Rebamipide has a definite curative effect on CSG of spleen-stomach weakness type，which can improve the pain and quality of life of patients， regulate the levels of PGE2 and EGF， decrease the recurrence of disease with good safety.